Background: We aimed to determine safety and efficacy of rituximab (R) in combination with repetitive high-dose therapy (HDT) as primary treatment for diffuse large B-cell lymphoma (DLBCL). was given before each cycle and 12 and 33 days after start of the last cycle of chemotherapy. Sixty-four patients given R-MegaCHOEP were compared with 29 patients who had received identical treatment without rituximab.
introduction
Treatment with combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like chemotherapy in combination with rituximab has become standard of care in all elderly and young low-risk patients with a primary diagnosis of CD20
+ diffuse large B-cell lymphoma (DLBCL) [1] [2] [3] [4] . In younger patients with high-risk features at diagnosis, the role of rituximab has not yet been defined. Treatment with CHOP therapy is clearly inadequate [5, 6] , while the role of rituximab awaits further study. Many attempts have been made to elucidate the role of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) in young high-risk patients. The results of phase III studies in this field are heterogeneous [7] [8] [9] [10] [11] [12] [13] [14] [15] . None of these studies used rituximab, and data on how rituximab might influence the results of high-dose chemotherapy are scarce.
In a series of phase I/II studies, we have established the feasibility, safety and efficacy of a new dose-escalated CHOP plus etoposide protocol (MegaCHOEP) involving repeated infusions of autologous peripheral blood stem cells [16, 17] . Here, we report on the combination of MegaCHOEP with six courses of rituximab (R-MegaCHOEP). Toxicity and efficacy of R-MegaCHOEP were retrospectively compared with results in a group of patients who had received MegaCHOEP without rituximab [17] .
patients and methods patients
Patients were eligible for inclusion if they were aged 18-60 years, with a primary diagnosis of CD20 + DLBCL and a serum lactate dehydrogenase (LDH) concentration above the upper normal limit. Individual written original article informed consent was mandatory. The protocol was approved by an independent ethics committee and trial conduct followed the rules of the Helsinki declaration. Lymphomas of the central nervous system (CNS), lymphoblastic or Burkitt-type lymphoma, secondary high-grade lymphoma, other malignancy, major organ dysfunction, known positivity for human immunodeficiency virus or active hepatitis were exclusion criteria. As repeated stem-cell mobilisation was planned, >25% bone marrow involvement by histology was an additional exclusion criterion. Enrolment of patients started in June 2001 and ended in February 2003. Eighty-nine patients were enrolled (the list of participating institutions is detailed under contributors). Seventeen patients did not fulfil inclusion criteria and were excluded from study treatment and analysis. Reasons for exclusion were correction of primary histological diagnosis by pathology review (n = 8), withdrawal of informed consent (n = 1), bone marrow involvement >25% (n = 3), CNS involvement (n = 1), LDH below upper normal limit (n = 1), concomitant disease (n = 2) or pretreatment of lymphoma (n = 1). Of the remaining 72 patients, 64 were confirmed as having CD20 + DLBCL and were finally included in the study.
control group
Twenty-nine patients with a diagnosis of DLBCL reviewed by an expert haematopathologist served as controls. These patients had received identical MegaCHOEP chemotherapy without rituximab. Recruitment of patients receiving MegaCHOEP without rituximab took place from September 1999 to May 2001, immediately before this study [17] . Inclusion and exclusion criteria were similar for both groups.
treatment
Patients with high tumour load and/or poor performance status were to receive a single dose of 2-mg vincristine and 100 mg/day of prednisone for 7 days. The MegaCHOEP protocol consisted of four courses of cyclophosphamide (C), adriamycin (H), vincristin (O), etoposide (E) and prednisolone (P). With course 1, C was given at a dose of 750 mg/m 2 on days 1 and 2, H at 35 mg/m 2 on days 1 and 2, O at 2 mg on day 1, E at 200 mg/m 2 on days 1-3 and P at 100 mg on days 1-5. With courses 2-4, the doses of C and E were increased: C was escalated to 3000 mg/m 2 on days 1 and 2 and E was given at 185 mg/m 2 twice daily (days 1-4).
Chemotherapy was given every 3 weeks if platelet count was >80/nl. Patients received the first of six infusions of rituximab (375 mg/m 2 ) 1 day before the first cycle of chemotherapy. The second to fifth infusions were given 12 days after start of each of chemotherapy cycles 1-4. The sixth infusion of rituximab was scheduled 33 days after start of the last chemotherapy cycle. This schedule resulted in the application of a minimum of two doses of rituximab before stem-cell mobilisation and harvest.
stem-cell transplantation and supportive therapy
Filgrastim at a dose of 480 lg was started on day 6 after cycle 1 of chemotherapy until 2 · 10 6 CD34 + progenitor cells/kg body weight could be harvested for transplantation after course 2. Using the same mobilisation regimen, peripheral blood progenitor cells were harvested again after the second course of chemotherapy and split into two collection products each of which needed to contain 2 · 10 6 CD34 + cells/kg. These harvests were re-infused into the patient after courses 3 and 4. If the yield of the second stem-cell collection was not sufficient for transplantation after courses 3 and 4 (<4 · 10 6 CD34 + cells/kg), a third collection after course 3 was mandatory. Prophylaxis of bacterial, fungal and viral infections has been described [17] .
statistics
The primary end point of this study was the feasibility of R-MegaCHOEP defined as the proportion of patients receiving therapy according to protocol. Safety was evaluated using the Bearman toxicity scale [18] and infectious complications were graded according to World Health Organisation (WHO) criteria. Efficacy was measured by calculating the complete remission (CR) rate, event-free survival (EFS) and overall survival (OS). Criteria of remission were used as published [19] . Remission status was evaluated by clinical examination and repetition of all diagnostic measures at least 3 months after the last course of therapy. Remission with any type of residual mass stable at least 2 months after final restaging was defined as CR or complete remission unconfirmed (CRu). Treatment failure was defined as death from any cause, progression of disease, salvage therapy or relapse. EFS and OS were measured from the start of therapy and estimated according to the method of Kaplan and Meier. The estimations at 3 years were calculated with 95% confidence intervals (CI). Differences in patient characteristics, nonhaematologic toxic effects and response rates were tested for significance by chi-square test and, if required, by Fisher's exact test. Differences in haematologic recovery in the numbers of CD34 + cells collected or infused between patients receiving rituximab or not were tested with the Mann-Whitney U test. Univariate analysis for the effect of rituximab on OS and EFS was done by the log-rank test. Multivariate analysis was done using the Cox regression model adjusting for the factors of the age-adjusted International Prognostic Index (aaIPI) [5] . All tests for significance were at the 5% significance level and not adjusted for multiple comparisons. All statistics were calculated in SPSS/ PC+ V 10.0.
results Sixty-four patients with DLBCL were treated with R-MegaCHOEP. Twenty-nine patients received identical chemotherapy without rituximab and served as controls. The major characteristics of the patients are shown in Table 1 . The patient cohort receiving treatment without rituximab had a significantly poorer performance status at diagnosis than Table 1) .
feasibility of treatment and dose intensity
Forty-six of 64 patients receiving R-MegaCHOEP (71.9%) completed all four courses of chemotherapy, while 26 of 29 patients (89.7%) receiving MegaCHOEP without rituximab completed all four courses (P = 0.057). In the latter group, one patient stopped therapy due to excessive toxicity after cycle 1 and two additional patients after cycle 2. In the R-MegaCHOEP group, eight patients (12.5%) stopped chemotherapy owing to excessive toxicity after cycle 1 (n = 3), cycle 2 (n = 1) or cycle 3 (n = 4). Three patients in the R-MegaCHOEP group (4.7%) failed to mobilise sufficient numbers of stem cells for all scheduled infusions, while none of the 29 patients receiving MegaCHOEP without rituximab experienced mobilisation failure. One patient stopped therapy due to protocol violation. Rituximab was discontinued without a documented reason in three patients after the last cycle of chemotherapy and in four patients after the fifth administration of rituximab. These cases also represent protocol violations. In three patients with complete chemotherapy (4.7%), excessive toxicity was given as the reason for discontinuation of rituximab ( Table 2 ). The median dose of cyclophosphamide administered was 98% of the planned dose in the MegaCHOEP-only group and was not statistically different from the 97% for the group of patients who received R-MegaCHOEP. The median duration of chemotherapy from the start of first course to recovery of platelets after the last course was 100 days with and without rituximab. Compared with eight cycles of CHOEP given at 21-day intervals [20] , the dose intensity of cyclophosphamide was 4.79-fold higher in patients receiving MegaCHOEP without rituximab and 4.92-fold higher in patients receiving R-MegaCHOEP. The dose intensity of etoposide was increased to 3.09-fold (without rituximab) or 3.08-fold (with rituximab).
haematologic toxicity and time between treatment courses
Haematologic recovery after course 1 (white blood cell > 1/nl, platelet count > 80/nl) occurred at a median of 13 days (range: 0-18) and 15 days (range: 0-21), respectively. Overall, there were no relevant differences concerning haematopoietic recovery in patients receiving MegaCHOEP with or without rituximab. The median time interval to the next course of therapy was 27 days (range: 16-70). All patients receiving autologous stem cells ultimately recovered their peripheral blood counts.
nonhaematologic toxicity
Oral mucositis, gastrointestinal toxicity and infection were the most important nonhaematologic toxic effects encountered. All other toxic effects were rare and usually mild (Figure 1 ). Seventy-eight per cent of patients experienced some grade of oral mucositis and 14.7% severe oral stomatitis with a significant difference between treatment groups (P = 0.048). There were no overall differences for gastrointestinal toxicity (40.0% without rituximab versus 36.3% with rituximab). Overall incidence of infectious complications did not differ between patients receiving MegaCHOEP with or without rituximab (65.4% versus 69.0%), but severe and lifethreatening infections (WHO grades 3 and 4) were more frequent in patients receiving rituximab (6.0% versus 18.5%, P = 0.003). Three of 64 patients (4.7%) receiving RMegaCHOEP died from infectious complications. There was no case of treatment-related mortality among the 29 patients receiving MegaCHOEP without rituximab.
mobilisation and re-infusion of haematopoietic stem cells
Three of 64 patients (4.7%) treated with R-MegaCHOEP failed to mobilise stem cells for at least one of the planned transplantations. There were no significant differences in the numbers of stem cells harvested between patients receiving therapy with or without rituximab during cycle 1, 2 or 3. The median yield of CD34 + progenitor cells was 15.1 and 7.2 · 10 6 /kg after courses 1 and 2, respectively. A third harvest was necessary in 11 of 79 patients (13.9%). At least 11 patients had more than two leukaphereses per mobilisation. The number of progenitor cells actually administered after courses 2, 3 and 4 were 6.1, 3.8 and 3.8 · 10 6 CD34 + cells/kg, respectively. There were no significant differences between patients treated with rituximab compared with patients receiving MegaCHOEP without rituximab. remission rate, time to treatment failure and survival Four patients (3 of 64 patients receiving rituximab) could not be evaluated for response to MegaCHOEP because they terminated therapy early without a report on the disease status at that time. Three patients died before first restaging after therapy, all due to infectious complications. These seven patients were counted as non-CR patients. Fifty of 64 patients (78.1%; 95% CI: 68.0% to 88.2%) achieved CR or CRu after treatment with R-MegaCHOEP. The CR rate of patients receiving no rituximab was 65.6% (95% CI: 44.2% to 86.9%). Eight of 58 patients (13.8%) had refractory disease after treatment with R-MegaCHOEP compared with 9 of 28 (32.1%) treated with MegaCHOEP alone (Table 3) . One patient experienced progressive disease after cycle 2 of MegaCHOEP and one patient after cycle 3 of R-MegaCHOEP; both patients progressed shortly after stopping MegaCHOEP treatment due to toxicity. In all other patients with progression, this occurred within 2 months of final restaging. Of the 50 patients achieving CR/CRu after R-MegaCHOEP, 4 patients relapsed between 9.7 and 33.7 months after the start of the therapy. These four patients had completed all chemotherapy. Only one relapse occurred later than 2 years from start of treatment and none later than 3 years. After 3 years, EFS was 72.7% (95% CI: 60.8% to 84.6%) and OS was 78.7% (95% CI: 67.5% to 89.9%) (Figure 2 ). In the 29 patients who received MegaCHOEP without rituximab, 3-year OS and EFS were significantly shorter (OS 55.0%, 95% CI: 35.8% to 74.2%, P = 0.045 and EFS 47.2%, 95% CI: 28.6% to 65.8%, P = 0.013). In a Cox regression model adjusting for the factors of the aaIPI (stage and performance status), patients receiving rituximab had a relative risk of 0.5 of treatment failure (P = 0.041) ( Table 4) . Treatment with rituximab showed borderline significance with respect to OS (P = 0.054). In a Cox model adjusting for the aaIPI score, there was a statistically significant benefit for patients receiving rituximab with respect to both OS and EFS (data not shown).
late effects: myelodysplasia and secondary neoplasia
One patient in the R-MegaCHOEP group (n = 64) and one patient in the MegaCHOEP-only group (n = 29) developed secondary acute myeloblastic leukaemia 14 and 33 months, respectively, after start of therapy. No other secondary neoplasias have been reported so far. original article
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This study demonstrates the feasibility and efficacy of a highdose chemotherapy programme consisting of four doseescalated courses of CHOP plus etoposide given in combination with rituximab. In previous studies, we were able to demonstrate that MegaCHOEP without rituximab could be completed by 90.2% of all patients; this compares favourably to most other HDT protocols where up to 40% of failures before the actual HDT were reported [7, 12] . The number of patients progressing on therapy was very low in patients receiving MegaCHOEP only (1 of 110 patients). However, in that study, 21 of 110 patients had less than CR/CRu at the end of therapy [16] . We attempted to tackle this problem by early application of rituximab with MegaCHOEP. Although some reports addressed safety, feasibility and efficacy of stem-cell mobilisation, HDT and ASCT in combination with rituximab [21] [22] [23] [24] [25] [26] [27] [28] [29] , no other studies in the field of primary treatment of DLBCL have been reported. When combined with rituximab, 71.9% of patients completed all four cycles of MegaCHOEP chemotherapy compared with 89.7% of patients receiving identical chemotherapy without rituximab, even though the average performance status at study entry had been poorer in the control group. This might indicate that the addition of rituximab compromises feasibility of MegaCHOEP treatment-although it still remained better than in many other HDT trials in aggressive nonHodgkin's lymphoma.
There are at least two possible reasons for the lower percentage of patients being able to receive R-MegaCHOEP on time compared with MegaCHOEP. Firstly, we observed a significantly higher rate of severe infections with R-MegaCHOEP than with MegaCHOEP alone (18.5% compared with 6.0% of all cycles). Such findings have not been reported for combinations of rituximab with standarddose chemotherapy [1, 2] . Khouri et al. [21] report on 67 patients with relapsed or progressive aggressive lymphoma receiving HDT followed by ASCT plus rituximab and compared results and toxicity with 30 patients receiving the same therapy without rituximab. Differences in toxicity or treatment-related mortality were not seen in this study. Characteristics of both cohorts in their study with respect to IPI (IPI > 1: 12% R + HDT and 0% HDT) were much better than in our trial (IPI > 1: 76.2% R-MegaCHOEP; 79.3% MegaCHOEP) and the overall incidence of infectious episodes was lower. The incidence of severe infections (grade 3/4) was not reported by Khouri et al. An impact of rituximab on infectious complications may only become clinically relevant in combination with very high doses of chemotherapy causing severe mucositis in a considerable percentage of patients treated.
Secondly, we observed three cases of mobilisation failure with R-MegaCHOEP, whereas none of the patients receiving MegaCHOEP without rituximab had experienced this complication. In a previous study of MegaCHOEP without rituximab, only 1 of 110 patients had mobilisation failure [16] . Other investigators found no indication for a negative impact of rituximab on stem-cell mobilisation [24, 28] . As neither these nor our studies compared stem-cell mobilisation with and without rituximab in a randomised fashion and as the number of cases reported is still small, definitive conclusions are not possible.
Treatment-related mortality (4.7%) was slightly higher for R-MegaCHOEP than with MegaCHOEP alone. Again, it cannot be excluded that the higher rate of serious infections is responsible for elevated treatment-related mortality. The potential disadvantages of adding rituximab to MegaCHOEP treatment were outweighed by a substantially better treatment outcome. Patients with DLBCL receiving MegaCHOEP with rituximab had a better OS and EFS than patients receiving the same chemotherapy without rituximab. Even with the small number of patients in the nonrituximab group, this was confirmed in a Cox regression model correcting for the aaIPI score or the individual factors of aaIPI. The difference between patients treated with or without rituximab mostly lies in a lower fraction of patients progressing under or immediately after the end of therapy (12.5% versus 31.0%). This observation is well in line with reports on the combination of rituximab with standard-dose chemotherapy [1] . Rituximab thus seems to help resolve the most urgent problem in patients with high-risk aggressive NHL-early progression.
R-MegaCHOEP is currently being compared with a nontransplant chemo-immunotherapy (R-CHOEP given every 2 weeks) in a randomised phase III trial of the Deutsche Studiengruppe Hochmaligne Non-Hodgkin-Lymphome (DSHNHL).
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